Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA clears TRIA's acne treatment device for OTC

This article was originally published in The Rose Sheet

Executive Summary

TRIA Beauty is planning a spring 2010 launch for its blue light device designed for home treatment of acne, after receiving over-the-counter clearance from FDA, firm announces. The device will debut on TRIABeauty.com and at select retailers. Firm says its blue light technology is 10 times more powerful than other OTC blue light devices, and that it delivers clear skin faster with shorter treatment times. TRIA cites clinical studies demonstrating the technology "cleared breakouts as quickly and effectively as professional blue light treatments." The company's home-use permanent laser hair-removal device received FDA approval in 2007; it retails for $595 (1"The Rose Sheet" Nov. 9. 2009)

You may also be interested in...



TRIA Enhances Home Hair-Removal Device, Lowers Price In Time For Holidays

TRIA Beauty has upgraded its laser hair-removal device, knocked $200 off the price and launched a multimedia marketing campaign to entice shoppers this holiday season

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel